⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237770 | 0.91 | — | — | |
| SCHEMBL16086012 | 0.80 | — | — | |
| SCHEMBL16603037 | 0.65 | — | — | |
| SCHEMBL17953964 | 0.62 | — | — | |
| SCHEMBL1592805 | 0.62 | — | — | |
| SCHEMBL1592783 | 0.62 | — | — | |
| SCHEMBL3694516 | 0.61 | PNMT (0.30) | — | |
| SCHEMBL3694424 | 0.61 | PNMT (0.30) | — | |
| SCHEMBL28808639 | 0.60 | — | — | |
| SCHEMBL2496236 | 0.60 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20210378964-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC | 2021-12-09 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20200030239-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2020-01-30 | — | — | US | disclosed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190133955-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2014-12-18 | — | — | US | disclosed |
| EP-2809668-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-12-10 | — | — | EP | disclosed |
| WO-2014081906-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2013114332-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-08 | — | — | WO | disclosed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |